Treatment-Resistant Depression: Results of Latest Electromagnetic Stimulation Study Show Promise

WASHINGTON, D.C. -- An investigational treatment employing electromagnetic stimulation relieved depression in 25 patients whose depression failed to respond to conventional treatment, report Emory University researchers at this week's American Psychiatric Association meeting.

Scores on depression rating scales administered to study subjects before, during and after the new treatment "were significantly improved at all time points compared to baseline," says first author Yvonne M. Greene, M.D., in the abstract; Dr. Greene is a neurosciences fellow at the Emory University School of Medicine and has collaborated on the open trial with William McDonald, M.D., associate professor of psychiatry and behavioral sciences at the Emory University School of Medicine, and others.

"Sixty-four percent of patients were rated 'very much improved' or 'much improved' on the (CGIC) Clinical Global Impression of Change and 40 percent of patients had an equal to or greater than 50 percent decrease in HDRS (Hamilton Depression Rating Scale) scores at the end of treatment week two. Forty percent of patients were rated 'very much improved' or 'much improved' on the CGIC and 32 percent of patients had an equal to or greater than 50 percent decrease in HDRS scores at the end of the four-week followup.

"These results suggest rTMS (repetitive transcranial magnetic stimulation) may be a viable option for patients with treatment-resistant depression," the authors say.

Prior to receiving rTMS, "There were an average of seven antidepressant failures per patient and eight patients had failed electroconvulsive therapy (ECT)," they say.

"rTMS involves passing current through an electromagnetic coil to generate a magnetic field," they explain. "The magnetic field acts as the medium between electricity in the coil and induced electrical currents in the brain. The current depolarizes neurons in the brain up to a depth of about two centim

Contact: Sarah Goodwin
Emory University Health Sciences Center

Page: 1 2

Related medicine news :

1. Heart transplant survival: Results may be key to rejection prevention, detection, treatment
2. Docetaxel versus paclitaxel in breast cancer Results of worlds first head to head trial
3. Results from first clinical trial using GVG to treat addiction
4. Results of first chronic treatment study with oral EXANTA(TM) (ximelagatran)
5. Media Advisory-- Results of California autism epidemiology study to be unveiled
6. Results of Yale study confirm aspirin helpful in preventing a first heart attack
7. Results of NUVANCE (IL-4 receptor) in Phase I/II study in asthma patients featured at AAAAI Late-Breaker Abstract and Asthma Therapy Sessions
8. Yale study shows way to re-stimulate brain cell growth: Results could boost understanding of Alzheimers, other brain disorders
9. Results of NUVANCE phase I/II asthma trial presented
10. ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia
11. UI Study Yields Encouraging Results For New Breast Cancer Treatment

Post Your Comments:

(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains ... possible to save lost souls in the Philippines. “The Journey: From the Mountains to ... dedicated teacher of the Bible. She has taught all ages and currently teaches a ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... ... 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of ... innovative new design of the shoulder pad. The shoulder pad provides optimal support ... your pain while using cold therapy. By utilizing ice and water that is circulated ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... that we intend to develop to enable prevention of a major side effect ... hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... for the 49th Congress of the International Society of Paediatric Oncology (SIOP) ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. ...
Breaking Medicine News(10 mins):
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., a ... today announced that it has been ranked #1 by its ... Book™ Rankings 2017 User Survey. ZirMed was recognized as ... large hospitals and medical centers over 200 beds and holds ... healthcare technology user survey history. ...
(Date:9/18/2017)... , Sept. 18, 2017 ... fields of bioinformatics and immune engineering, today ... protective avian influenza A (H7N9) vaccine. ... related to seasonal influenza and presents a ... on prior exposure to be effective. Using ...
(Date:9/12/2017)... YORK , Sept. 12, 2017   EcoVadis , the leading ... has published the first annual edition of its Global CSR Risk and ... companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 ... ... Index ...
Breaking Medicine Technology:
Cached News: